439 active not recruiting. 439 Phase 2, 106 Phase 1, 10 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 439 | Active not recruiting 439 |
| Phase 1 | 106 | Active not recruiting 106 |
| Phase 3 | 10 | Active not recruiting 10 |
Follow Lymphatic Diseases: new trials by email Literature Review of Lymphatic Diseases trials Research Report on Lymphatic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) Venetoclax - Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma | Phase 2 | Active not recruiting | AbbVie | 14 | 2026-03-17 | 2026-09-09 |
| A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease AZ-3102 - GM2 Gangliosidosis, Niemann-Pick Type C Disease | Phase 2 | Active not recruiting | Azafaros B.V. | 21 | 2026-02-04 | 2026-10-21 |
| A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia Blinatumomab, Mini-CVD, MTX/ARA-C - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 3 | 2026-01-30 | 2026-08-18 |
| Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma Glofitamab, Gemcitabin, Oxaliplatin - Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 40 | 2026-01-01 | 2026-03-18 |
| Efficacy and Safety of Sequential Autologous Hematopoietic Stem Cell Transplantation Combined With Tafasitamab, Lenalidomide, and Standard Immunochemotherapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma Treatment with the Tafa+Len+ standard immunotherapy regimen (e.g., R-ICE, R-DHAP, R-GDP, etc.) - Relapsed/Refractory Diffuse Large B Cell Lymphoma | Phase 2 | Active not recruiting | The First Affiliated Hospital of Soochow University | 25 | 2026-01-01 | 2026-06-02 |
| A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia Blinatumomab - Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Amgen | 104 | 2025-12-08 | 2026-10-05 |
| Ulcer Plants: Highly Accessible Plant Antiseptics for Use in Remote Areas of PNG - Second Trial Ficus septica exudate, Active Comparator: Savlon antiseptic cream (cetrimide with chlorhexidine digluconate) - Cutaneous Ulcer Disease, Skin Sores | Phase 2 | Active not recruiting | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 222 | 2025-11-03 | 2026-07-16 |
| Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas Pemigatinib - Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma | Phase 2 | Active not recruiting | University of Utah | 1 | 2025-10-03 | 2026-07-09 |
| Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL Orelabrutinib, Zuberitamab, Cyclophosphamide - Marginal Zone Lymphoma(MZL) | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 65 | 2025-10-01 | 2026-04-02 |
| IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers DOMVANALIMAB + ZIMBERELIMAB, DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4 - Peritoneal Mesothelioma, Gestational Trophoblastic Tumor | Phase 2 | Active not recruiting | Hospices Civils de Lyon | 27 | 2025-10-01 | 2026-06-25 |
| Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma Orelabrutinib (ICP-022), radiotherapy, Rituximab (R) - Marginal Zone Lymphoma of Ocular Adnexal, Marginal Zone Lymphoma(MZL) | Phase 2 | Active not recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 39 | 2025-09-19 | 2025-11-25 |
| JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma JS203 in combination with gemcitabine and oxaliplatin, JS203 in combination with ifosfamide, carboplatin and etoposide, JS203 in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone - B-cell Non-Hodgkin's Lymphoma | Phase 2 | Active not recruiting | Shanghai Junshi Bioscience Co., Ltd. | 180 | 2025-08-17 | 2026-09-04 |
| Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers Pirtobrutinib - Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 2 | Active not recruiting | Eli Lilly and Company | 13 | 2025-08-07 | 2026-04-17 |
| Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH Selinexor, Thalidomide (100mg), Dexamethasone - Langerhans Cell Histiocytosis (LCH) | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 40 | 2025-08-01 | 2025-10-02 |
| Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia blinatumomab combined with venetoclax as maintenance therapy - B-Cell Acute Lymphoblastic Leukemia, Adult | Phase 2 | Active not recruiting | Zhejiang University | 24 | 2025-06-01 | 2025-09-30 |
| Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma CD22/CD19 CAR-T cell immunotherapy - Lymphoma | Phase 2 | Active not recruiting | Daihong Liu | 50 | 2025-04-01 | 2025-07-30 |
| Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study Psilocybin combined with Psychotherapy - Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe | Phase 2 | Active not recruiting | McMaster University | 16 | 2025-03-21 | 2026-08-31 |
| A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer Cobolimab, Dostarlimab - Melanoma, Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | GlaxoSmithKline | 83 | 2025-03-06 | 2025-11-12 |
| GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma Pirtobrutinib, Rituximab, Venetoclax - Mantle Cell Lymphoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 50 | 2025-01-30 | 2026-11-02 |
| A Study of Enasidenib in People With T-Cell Lymphoma Enasidenib, Rituximab - T-cell Lymphoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 2 | 2024-12-24 | 2026-08-20 |
Showing 20 of 439. Sign in to see all of them.
Lymphoma (81) · Leukemia, Lymphocytic, Chronic, B-Cell (66) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (63) · Lymphoma, Non-Hodgkin (58) · Lymphoma, Large B-Cell, Diffuse (57) · Lymphoma, Mantle-Cell (50) · Lymphoma, Follicular (48) · Multiple Myeloma (38) · Recurrence (34) · Lymphoma, B-Cell (33) · Hodgkin Disease (32) · Lymphoma, B-Cell, Marginal Zone (30) · Leukemia (27) · Leukemia, Myeloid, Acute (26) · Hematologic Neoplasms (25)
Hemic and Lymphatic Diseases (439) · Neoplasms by Histologic Type (416) · Immune System Diseases (412) · Immunoproliferative Disorders (410) · Lymphoproliferative Disorders (406) · Neoplasms (399) · Lymphoma (223) · Hematologic Diseases (193) · Lymphoma, Non-Hodgkin (168) · Leukemia, Lymphoid (130) · Leukemia (124) · Pathological Conditions, Signs and Symptoms (113) · Pathologic Processes (112) · Disease Attributes (107)
Cyclophosphamide (87) · Rituximab (87) · Doxorubicin (49) · venetoclax (45) · Prednisone (42) · Vincristine (41) · Specimen Handling (39) · Biopsy (38) · acalabrutinib (35) · ibrutinib (35) · Etoposide (32) · Lenalidomide (30) · Magnetic Resonance Spectroscopy (30) · obinutuzumab (29) · Cytarabine (25)
National Cancer Institute (NCI) (63) · M.D. Anderson Cancer Center (37) · City of Hope Medical Center (22) · Memorial Sloan Kettering Cancer Center (22) · St. Jude Children's Research Hospital (12) · Dana-Farber Cancer Institute (10) · Genmab (7) · Acerta Pharma BV (6) · Hoffmann-La Roche (6) · University of Washington (6) · Gruppo Italiano Malattie EMatologiche dell'Adulto (5) · Christian Buske (4) · Institute of Hematology & Blood Diseases Hospital, China (4) · Stichting Hemato-Oncologie voor Volwassenen Nederland (4) · The First Affiliated Hospital of Soochow University (4)
United States (322) · China (54) · Italy (51) · Spain (50) · France (49) · Canada (44) · United Kingdom (41) · Australia (32) · Belgium (28) · Germany (26) · Netherlands (22) · Poland (21) · Japan (20) · South Korea (20) · Denmark (17)
Alex F Herrera (5) · Alison Moskowitz, MD (4) · Christian Buske, MD (4) · David S Hong (3) · Elias Jabbour (3) · Filip Janku (3) · Jae Park, MD (3) · Jan A Burger (3)
PMID 41671463, PMID 34393061, PMID 39319495, PMID 40550489, PMID 31401903, PMID 34515338, PMID 27503501, PMID 28714866, PMID 34398557, PMID 34608724, PMID 34797699, PMID 35622074, PMID 37505794, PMID 39563886, PMID 40135712, PMID 40472301, PMID 42411504, PMID 42541678, PMID 10552938, PMID 15486066, PMID 20516455, PMID 21487108, PMID 22225488, PMID 22285199, PMID 22940833, PMID 24174627, PMID 24327518, PMID 24659631, PMID 24699307, PMID 25331113, PMID 25555420, PMID 26182309, PMID 26337493, PMID 26430171, PMID 26432046, PMID 26586415, PMID 26640039, PMID 26641137, PMID 26729345, PMID 26907630, PMID 26982511, PMID 27118452, PMID 27424289, PMID 27601462, PMID 27760761, PMID 28049639, PMID 28053024, PMID 28089238, PMID 28408462, PMID 28672195
U10CA180820 (34), 2023 (19), U24CA196172 (18), P30CA033572 (15), U10CA180886 (10), 2017 (9), 2019 (7), 2015 (5), 2018 (5), U10CA180888 (5), 2014 (4), U10CA180821 (3), 2016 (2), P30CA015083 (2), P30CA015704 (2)